Docoh
Loading...

SLRX Salarius Pharmaceuticals

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 16, 2021, Salarius Pharmaceuticals, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Four proposals were submitted to stockholders as described in the Proxy Statement for the Annual Meeting and voted on at the Annual Meeting. The proposals and the results of the stockholder votes are as follows

1. Proposal to elect two Class III directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified:

NomineeVotes ForWithheldBroker

Non-Votes
Tess Burleson 11,267,742 759,606 12,458,951
Paul Lammers 11,268,242 759,10612,458,951


2. Proposal to provide a non-binding advisory vote on the compensation of our named executive officers:

Votes For Votes Against AbstentionsBroker Non-Votes
11,003,098 830,994 193,25612,458,951


3. Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent auditors for the 2021 fiscal year:



Votes For Votes Against AbstentionsBroker Non-Votes
23,584,404 763,263 138,63212,458,951


4. Proposal to provide a non-binding advisory vote on the frequency of holding an advisory vote on named executive officer compensation:

One YearTwo Years Three Years AbstentionsBroker Non-Votes
11,257,837162,599 465,581 141,33112,458,951